Product Center
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-02-18
- Views:
(Summary description)Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully held
(Summary description)Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-02-18 11:39
- Views:
Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
Herpes zoster (HZ) is caused by the varicella-zoster virus (VZV). Primary infection with this virus initially leads to chickenpox, after which the virus migrates from skin lesions and becomes latent in cranial ganglia, dorsal root ganglia, and autonomic ganglia along the neural axis. As people age or when their body's resistance decreases due to certain stimuli, VZV can be reactivated and cause herpes zoster. The general population is susceptible to VZV. Serological evidence shows that the VZV infection rate in adults is as high as over 90%, so the population is generally likely to develop herpes zoster. Herpes zoster can occur at any age, but its incidence rises significantly with increasing age. Herpes zoster not only affects the physical and mental health of patients, leading to a decline in their quality of life, but also imposes a significant disease burden and public health problem on families and society.
Our company has independently developed a recombinant herpes zoster vaccine (CHO cells), which incorporates a patented gE protein sequence, retains the advantageous antigenic epitopes, and innovatively employs a dual adjuvant system. This vaccine can effectively stimulate a specific immune response against VZV. Pre-clinical study data demonstrate that this vaccine induces stronger cell-mediated immune responses in animal models, suggesting potentially enhanced immunogenicity. Additionally, its high expression level of antigenic proteins may help reduce industrial production costs. If successfully approved for market, this vaccine will significantly improve the current supply of herpes zoster vaccines, offering the public a cost-effective vaccination option while strengthening our company’s competitive edge in the vaccine sector.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
